International Symposium on Amyotrophic Lateral Sclerosis/Motor Neurone Disease. Glasgow, GBR, 1997/11/02.
In health care, choices are constantly being made about alternative uses of scarce resources, and health economics offers a framework for analysing these choices and for improving resource allocation.
In cost-effectiveness analysis, the costs and consequences of alternatives are systematically measured and compared, with the objective of achieving maximum health gain with the available resources.
Treatment options for patients with ALS/MND are severely limited, but riluzole has been shown to offer modest improvements in survival.
However, decision-makers are likely to want convincing evidence on the cost-effectiveness of this therapy before recommending widespread adoption.
Here, some initial estimates of cost-effectiveness are provided, using published effectiveness data and considering only the costs of therapy and of tracheostomy, Compared with placebo, the incremental cost per life year gained of 50 mg/day of riluzole is £45 630, and of 100 mg/day is £44 890.
Increasing the estimated costs of tracheostomy reduces the cost per life year gained of 50 mg/day to £34 940.
However, if quality of life during the increased period of survival is 80% of full health, the cost per quality adjusted life year gained of 50 mg/day becomes £57 040.
These cost-effectiveness ratios are well in excess of the range that is normally considered to be acceptable in UK health technology assessment. (...)
Mots-clés Pascal : Sclérose latérale amyotrophique, Neurone moteur maladie, Survie, Analyse coût efficacité, Coût, Qualité vie, Riluzole, Chimiothérapie, Neuroprotecteur, Royaume Uni, Europe, Traitement, Economie santé, Homme, Benzothiazole, Système nerveux pathologie, Système nerveux central pathologie, Moelle épinière pathologie, Maladie dégénérative, Trachéostomie
Mots-clés Pascal anglais : Amyotrophic lateral sclerosis, Motor neuron disease, Survival, Cost efficiency analysis, Costs, Quality of life, Riluzole, Chemotherapy, Neuroprotective agent, United Kingdom, Europe, Treatment, Health economy, Human, Benzothiazole, Nervous system diseases, Central nervous system disease, Spinal cord disease, Degenerative disease, Tracheostomy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0142455
Code Inist : 002B02B10. Création : 16/11/1999.